Cassava Sciences ( (SAVA) ) just unveiled an announcement.
On January 24, 2025, the Delaware Court of Chancery approved a settlement related to Cassava Sciences’ 2020 Cash Incentive Bonus Plan, leading to amendments by the company’s board on March 6, 2025. These amendments include conditions for cash bonuses tied to market capitalization and FDA approval of simufilam, with specific provisions for the Chairman, President, and CEO roles, although no bonuses have been paid to date.
More about Cassava Sciences
Cassava Sciences, Inc. operates in the biotechnology industry, focusing on developing innovative treatments for neurodegenerative diseases, with a primary emphasis on Alzheimer’s disease. The company’s market focus includes advancing its lead drug candidate, simufilam, through clinical trials and regulatory approval processes.
YTD Price Performance: -2.91%
Average Trading Volume: 2,259,218
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $129M
See more insights into SAVA stock on TipRanks’ Stock Analysis page.
Trending Articles:
Questions or Comments about the article? Write to editor@tipranks.com